Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 12/20 | 1.00 |
| ▸ | INSR | P06213 | 6/20 | 0.85 |
| ▸ | LYN | P07948 | 6/20 | 0.85 |
| ▸ | LCK | P06239 | 6/20 | 0.85 |
| ▸ | KDR | P35968 | 6/20 | 0.85 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.85 |
| ▸ | FLT3 | P36888 | 4/20 | 0.85 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.85 |
| ▸ | FLT4 | P35916 | 3/20 | 0.85 |
| ▸ | CSF1R | P07333 | 3/20 | 0.85 |
| ▸ | BLK | P51451 | 3/20 | 0.85 |
| ▸ | AURKA | O14965 | 2/20 | 0.85 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.85 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.85 |
| ▸ | MARK3 | P27448 | 2/20 | 0.85 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.85 |
| ▸ | NEK2 | P51955 | 2/20 | 0.85 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.85 |
| ▸ | STK3 | Q13188 | 2/20 | 0.85 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11345526 | 0.97 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL5936219 | 0.93 | IGF1R (0.86) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL5936202 | 0.93 | IGF1R (0.86) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL5936199 | 0.93 | IGF1R (0.86) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL6215783 | 0.92 | IGF1R (0.85) | IGF1RINSRLYNLCKKDR | |
| Dimethylcarbate SCHEMBL6217753 | 0.92 | IGF1R (0.85) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL5936235 | 0.92 | IGF1R (0.97) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL5936382 | 0.92 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL5936262 | 0.92 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL5936264 | 0.92 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139484-B9 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2139484-B1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8481001-B2 | Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer | EXELIXIS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481001-B2 | Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer | EXELIXIS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8222256-B2 | Methods of using IGFIR and ABL kinase modulators | EXELIXIS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222256-B2 | Methods of using IGFIR and ABL kinase modulators | EXELIXIS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8211929-B2 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211929-B2 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090232828-A1 | Methods of Using IGFIR and ABL Kinase Modulators | EXELIXIS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| WO-2008124161-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080193462-A1 | Inhibiting tumor cell growth in subject by administering to said subject a combination of a cytotoxic or a chemotherapeutic agent and a composition comprising an insulin-like growth factor receptor-1 (IGF-1R) inhibitor; demonstrating specific approaches to enhance therapeutic window of IGF-1R inhibition | NATIONAL INSTITUTES OF HEALTH- DIRECTOR DEITR | 2008-08-14 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008005538-A2 | METHODS OF USING IGF1R AND ABL KINASE MODULATORS | EXELIXIS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| CN-1264844-C | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-D) pyrimidie derivatives | NOVARTIS AG (CH) | 2006-07-19 | — | — | CN | disclosed |
| CN-1531538-A | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-D) pyrimidie derivatives | ��˹��ŵ�� | 2004-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | IGF1R, INSR, ERBB3 | IGF1R 1/4885INSR 2/4885LYN 924/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | IGF1R 2279/4885INSR 1830/4885LYN 175/4885 |
| US-20080193462-A1 | Inhibiting tumor cell growth in subject by administering to said subject a combination of a cytotoxic or a chemotherapeutic agent and a composition comprising an insulin-like growth factor receptor-1 (IGF-1R) inhibitor; demonstrating specific approaches to enhance therapeutic window of IGF-1R inhibition | IGF1R, IGFBP1, IGFBP2 | IGF1R 1/4885INSR 14/4885LYN 1634/4885 |
| US-20090232828-A1 | Methods of Using IGFIR and ABL Kinase Modulators | IGF1R, ABL2, ABL1 | IGF1R 1/4885INSR 9/4885LYN 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.